Marion S.
- Country
- Germany
- Department
- Medizinische Klinik und Poliklinik III
Research Overview
- Phase 1 Open-Label Dose Escalation and Expansion Study of CLN-049 in Acute Myeloid Leukemia with Measurable Residual Disease
- Phase 1 Evaluation of Allo-RevCAR01-T-CD123 in CD123 Positive Hematologic Malignancies, Including Acute Myeloid Leukemia (AML)
- Long-term Follow-up of Gene-Modified Cell Therapy with Brexucabtagene Autoleucel and Axicabtagene Ciloleucel in Solid and Hematological Malignancies
Data & Insights
Has run more than one trial at 45 of 135 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of blood cancers, with particular emphasis on acute myeloid leukemia (AML) and its variants, including cases with measurable residual disease.
- Relapsed/Refractory AML
- B-cell Malignancies
- Non-Hodgkin Lymphoma
Their research extends to both newly diagnosed and treatment-resistant cases.
Cell-Based Therapies
The investigator focuses on innovative gene-modified T cell treatments and their applications in various hematologic conditions. Their work includes monitoring long-term outcomes and safety profiles of these therapeutic approaches.
- CAR T-cell Therapy
- Gene-Modified Cell Treatments
- Cellular Immunotherapy
Special attention is given to post-treatment monitoring and long-term patient outcomes.
Combination Therapeutics
The investigator explores novel therapeutic combinations for blood cancers, including the integration of monoclonal antibodies with established treatments.
- Immunotherapy Combinations
- Targeted Therapies
- Novel Drug Development
Research includes assessment of treatment efficacy in various patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.